E2F3a is critically involved in epidermal growth factor receptor-directed proliferation in ovarian cancer

Cancer Research

Volumn 70, Issue 11, 2010, Pages 4613-4623

  Reimer, Daniel ^a   Hubalek, Michael ^a   Riedle, Svenja ^b   Skvortsov, Sergej ^a   Erdel, Martin ^c   Concin, Nicole ^a   Fiegl, Heidi ^a   Müller Holzner, Elisabeth ^a   Marth, Christian ^a   Illmensee, Karl ^d   Altevogt, Peter ^b   Zeimet, Alain G ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c Krankenhaus der Barmherzigen Schwestern Linz   (Austria)

^d Genesis Fertility Center   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; INTERFERON REGULATORY FACTOR 1; INTERFERON REGULATORY FACTOR 2; LAPATINIB; MESSENGER RNA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR E2F2; TRANSCRIPTION FACTOR E2F3; TRANSCRIPTION FACTOR E2F3A; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL PROLIFERATION; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; MESOTHELIUM CELL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

CELL GROWTH PROCESSES; CELL LINE, TUMOR; E2F3 TRANSCRIPTION FACTOR; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; INTERFERON REGULATORY FACTOR-1; INTERFERON REGULATORY FACTOR-2; OVARIAN NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFECTION; UP-REGULATION;

EID: 77953143873     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-3551     Document Type: Article

References (32)

1. Lafky JM, Wilken JA, Baron AT, Maihle NJ. Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochim Biophys Acta 2008;1785: 232-265
2. Stadlmann S, Gueth U, Reiser U, et al. Epithelial growth factor receptor status in primary and recurrent ovarian cancer. Mod Pathol 2006; 19:607-610
3. Psyrri A, Kassar M, Yu Z, et al. Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer. Clin Cancer Res 2005;11:8637-8643
4. Meert AP, Martin B, Delmotte P, et al. The role of EGFR expression on patient survival in lung cancer: a systematic review with metaanalysis. Eur Respir J 2002;20:975-981 (Pubitemid 35175137)
5. Lavoie JN, Rivard N, L'Allemain G, Pouysségur J. A temporal and biochemical link between growth factor-activated MAP kinases, cyclin D1 induction and cell cycle entry. Prog Cell Cycle Res 1996;2:49-58.
6. Chen YY, Rabinovitch PS. Altered cell cycle responses to insulin-like growth factor I, but not platelet-derived growth factor and epidermal growth factor, in senescing human fibroblasts. J Cell Physiol 1990; 144:18-25. (Pubitemid 120027266)
7. Dimova DK, Dyson NJ. The E2F transcriptional network: old acquaintances with new faces. Oncogene 2005;24:2810-2826
8. Stevens C, La Thangue N. E2F and cell cycle control: a double-edged sword. Arch Biochem Biophys 2003;412:157-169
9. Black AR, Azizkhan-Clifford J. Regulation of E2F: a family of transcription factors involved in proliferation control. Gene 1999;237:281-302.
10. Takahashi Y, Rayman JB, Dynlacht BD. Analysis of promoter binding by the E2F and pRB families in vivo: distinct E2F proteins mediate activation and repression. Genes Dev 2000;14:804-816 (Pubitemid 30215000)
11. Attwooll C, Lazzerini Denchi E, Helin K. The E2F family: specific functions and overlapping interests. EMBO J 2004;23:4709-4716
12. Lazzerini Denchi E, Helin K. E2F1 is crucial for E2F-dependent apoptosis. EMBO Rep 2005;6:661-668
13. Adams MR, Sears R, Nuckolls F, Leone G, Nevins JR. Complex transcriptional regulatory mechanisms control expression of the E2F3 locus. Mol Cell Biol 2000;20:3633-3639
14. He Y, Armanious MK, Thomas MJ, Cress WD. Identification of E2F3B, an alternative form of E2F-3 lacking a conserved N-terminal region. Oncogene 2000;19:3422-3433 (Pubitemid 30479337)
15. Reimer D, Sadr S, Wiedemair A, et al. Heterogeneous cross-talk of E2F family members is crucially involved in growth modulatory effects of interferon-γ and EGF. Cancer Biol Ther 2006;5:771-776
16. Auersperg N, Siemens CH, Myrdal SE. Human ovarian surface epithelium in primary culture. In Vitro 1984;20:743-755 (Pubitemid 15171896)
17. Reimer D, Sadr S, Wiedemair A, et al. Clinical relevance of E2F family members in ovarian cancer - an evaluation in a training set of 77 patients. Clin Cancer Res 2007;13:144-151
18. Loeffler-Ragg J, Skvortsov S, Sarg B, et al. Gefitinib-responsive EGFR-positive colorectal cancers have different proteome profiles from non-responsive cell lines. Eur J Cancer 2005;41:2338-2346
19. Huang SM, Harari PM. Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest New Drugs 1999;17:259-269
20. DeGregori J. The genetics of the E2F family of transcription factors: shared functions and unique roles. Biochim Biophys Acta 2002;1602: 131-150
21. Blaustein A, Lee H. Surface cells of the ovary and pelvic peritoneum: a histochemical and ultrastructure comparison. Gynecol Oncol 1979; 8:34-43.
22. Nicosia SV, Johnson JH. Surface morphology of ovarian mesothelium (surface epithelium) and of other pelvic and extrapelvic mesothelial sites in the rabbit. Int J Gynecol Pathol 1984;3: 249-260
23. Chen C, Wells AD. Comparative analysis of E2F family member oncogenic activity. PLoS One 2007;2:e912.
24. Leone G, DeGregori J, Sears R, Jakoi L, Nevins JR. Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F. Nature 1997;387:422-426
25. Sears R, Ohtani K, Nevins JR. Identification of positively and negatively acting elements regulating expression of the E2F2 gene in response to cell growth signals. Mol Cell Biol 1997;17:5227-5235 (Pubitemid 27357621)
26. Abdollahi A, Gruver BN, Patriotis C, Hamilton TC. Identification of epidermal growth factor-responsive genes in normal rat ovarian surface epithelial cells. Biochem Biophys Res Commun 2003;307:188-197
27. Andersen P, Pedersen MW, Woetmann A, et al. EGFR induces expression of IRF-1 via STAT1 and STAT3 activation leading to growth arrest of human cancer cells. Int J Cancer 2008;122:342-349
28. Harada H, Kitagawa M, Tanaka N, et al. Anti-oncogenic and oncogenic potentials of interferon regulatory factors-1 and -2. Science 1993;259:971-974 (Pubitemid 23080666)
29. Yoshino A, Katayama Y, Watanabe T, et al. Therapeutic implications of interferon regulatory factor (IRF)-1 and IRF-2 in diffusely infiltrating astrocytomas (DIA): response to interferon (IFN)-β in glioblastoma cells and prognostic value for DIA. J Neurooncol 2005;74:249-260
30. Taniguchi T. Transcription factors IRF-1 and IRF-2: linking the immune responses and tumor suppression. J Cell Physiol 1997;173:128-130
31. Zeimet AG, Reimer D, Wolf D, et al. Intratumoral interferon regulatory factor (IRF)-1 but not IRF-2 is of relevance in predicting patient outcome in ovarian cancer. Int J Cancer 2009;124:2353-2360
32. Fujita T, Reis LF, Watanabe N, Kimura Y, Taniguchi T, Vilcek J. Induction of the transcription factor IRF-1 and interferon-β mRNAs by cytokines and activators of second-messenger pathways. Proc Natl Acad Sci U S A 1989;86:9936-9940